Experimental cell combo for tough breast cancer halted after just 2 patients
Disease control
Terminated
This early-phase study tested whether adding donor natural killer (NK) cells to standard antibody drugs (trastuzumab and pertuzumab) could help people with advanced HER2-positive breast cancer that had stopped responding to other treatments. Only 2 adults were enrolled before the…
Phase: PHASE1 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated May 12, 2026 13:43 UTC